Selumetinib

Drug Profile

Selumetinib

Alternative Names: ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 13 Jul 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Cincinnati Children's Hospital Medical Center; Merck & Co; National Cancer Centre (Singapore); National Cancer Institute (USA); Netherlands Cancer Institute; University Health Network; University of Cambridge; University of Liverpool
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thyroid cancer
  • Phase II Biliary cancer; Colorectal cancer; Gastrointestinal stromal tumours; Glioma; Neurofibromatoses; Non-small cell lung cancer; Uveal melanoma
  • Phase I/II Astrocytoma
  • Phase I Solid tumours
  • Preclinical Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Hepatocellular carcinoma; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 10 Jul 2017 National Cancer Institute plans a phase II trial for Solid tumours, Non-Hodgkin lymphoma, Histiocytosis (Second-line therapy or greater, In infants, In children, In adolescents, In adults, with MAPK pathway activation mutations) in USA (PO) (NCT03213691)
  • 02 Jun 2017 Phase-II clinical trials in Glioma (In adolescents, In children, In adults, Recurrent) in USA (PO)
  • 02 Jun 2017 Safety and efficacy data from a phase I/II trial in Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top